Hims & Hers struggles post market despite strong Q1 results and 2025 outlook

filo Although Hims & Hers Health ( NYSE: HIMS ) handily beat Street expectations on both lines in its Q1 financial results and also reiterated 2025 guidance, shares are down ~5% in post-market trading Monday. For the full year, revenue is projected at $2.3B-$2.

4B. Consensus is $2.32B.



For Q2, the.